Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-HTK03149
- Development stage
- Unknown
- Lead developer
- BC Cancer
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-HTK03149 is a radiolabeled small molecule positron emission tomography (PET) imaging agent that targets the prostate-specific membrane antigen (PSMA). It is based on the Lys-urea-Aad pharmacophore, where Glu in the original PSMA-targeting motif is replaced with L-2-aminoadipic acid (Aad), resulting in high tumor uptake and significantly reduced off-target accumulation in kidneys and salivary glands compared to earlier agents. This improved biodistribution profile enables clearer imaging of PSMA-expressing tumors, particularly prostate cancer lesions. 68Ga-HTK03149 is used for precise localization of PSMA-positive lesions to guide treatment decisions, especially as part of a theranostic pair with therapeutic agents such as 177Lu-HTK03170. The drug was developed at BC Cancer, Vancouver, Canada[1][2][4][6].
- Other names
- Gallium-68 HTK03149Gallium68 HTK03149Gallium 68 HTK03149
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 68Ga-HTK03149.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-HTK03149.